Limited evidence is available on the safety and efficacy of anticoagulants in non-valvular atrial fibrillation (AF) patients with concomitant hypertension. We investigated the safety and efficacy of 476 consecutive anticoagulated Chinese outpatients with non-valvular AF and hypertension. Occurrence of ischaemic stroke and major bleeding, and international normalized ratio (INR) values during these events were recorded. There was no significant difference in anticoagulation control between patients with or without hypertension. INRspecific incidence rates of the events were calculated, which showed no excessive risk for ischaemic stroke (2.5 vs 1.6% per year, P ¼ 0.22) or major bleeding (3.9 vs 3.2% per year, P ¼ 0.29) in non-valvular AF patients with or without hypertension. In multivariate analysis, congestive heart failure, smoking and high CHADS2 score were independent predictors for ischaemic stroke, whereas use of antiplatelet agents was an independent predictor for bleeding. It can be noted that hypertension was not associated with ischaemic stroke or major bleeding. Hypertensive patients who achieved target blood pressure control (o130/80 mm Hg) had a lower ischaemic stroke (0.9 vs 3.1% per year, P ¼ 0.01), but similar bleeding risk compared with those not achieving target blood pressure. Our findings demonstrate the effects of hypertension on the outcomes of warfarin therapy; further investigation is needed to clarify whether more aggressive antihypertensive therapy could result in better outcomes in hypertensive patients with non-valvular AF.
Introduction
In population studies, hypertension is the most common aetiological factor associated with atrial fibrillation (AF), whereas in hospital series, coronary artery disease and congestive heart failure are the most common associated cardiovascular diseases. 1, 2 In the general population, the risk of developing AF in patients with hypertension is 1.9 and 1.4 times higher than normotensive subjects in the Framingham 3 and Manitoba 4 studies, respectively. Although the absolute risk of developing AF among hypertensive patients is low, hypertension per se remains a major risk factor for AF because of its high prevalence in the general population.
The concomitant presence of hypertension and AF poses a higher risk and poorer outcome after stroke than those with AF alone. 5 Furthermore, hypertension is associated with an increased risk of stroke severity, which was not shown to be statistically significant. 6 As a result, hypertension is considered as one of the most common and important risk factors for the initiation of anticoagulation therapy in non-valvular AF. 7 On the other hand, hypertension is associated with an increased risk of intracranial haemorrhage. 8 There is even greater concern about this bleeding risk with anticoagulation among the Chinese population given the higher prevalence of haemorrhagic stroke in such subjects. 9 Indeed, the recommended lowest effective intensity of anticoagulation for non-valvular AF in Caucasians may not be applicable to Far Eastern patients. For example, a study from Japan reported that the lowest effective international normalized ratio (INR) for stroke prevention in their population was only 1.6. 10 As a result, there is a clinical dilemma on the use of anticoagulation therapy in Chinese non-valvular AF patients with concomitant hypertension. Currently, we are unaware of any data on the safety and efficacy of anticoagulation therapy in Chinese patients with hypertension and associated AF. The aim of this study was to investigate the safety and efficacy of anticoagulation among Chinese patients with non-valvular AF and hypertension.
Methods
In a retrospective analysis, we reviewed case records of consecutive anticoagulated patients with nonvalvular AF who were followed up in our cardiac outpatient clinic between 1 January 2001 and 31 March 2007. Most patients in our cardiac outpatient clinic were either referred from general practitioners and/or family physicians for further AF management or discharged from our hospital after hospitalization for AF, thus representing a selected AF population requiring specialist care. During this study period, we identified a total of 476 consecutive Chinese patients with either non-valvular paroxysmal AF or persistent AF who were receiving long-term anticoagulation therapy. Clinical data on the outcome events (ischaemic stroke, minor bleeding, major bleeding and intracranial haemorrhage) and their INR values during the events were retrieved from the medical records.
Definitions and clinical outcomes
Hypertension was defined as a systolic blood pressure X140 mm Hg, a diastolic blood pressure X90 mm Hg, or if the patient was prescribed antihypertensive medication(s). Diabetes mellitus was defined as a serum fasting glucose X7.0 mmol l À1 or on medications for diabetes. The diagnosis of congestive heart failure was validated with the use of the modified Framingham criteria. 11 The occurrence of AF was documented by a standard 12-lead electrocardiography, 24-h Holter recording or by a device electrogram recording during outpatient follow-up or subsequent hospital admission. The risk of stroke and thromboembolism were assessed using the CHADS2 scheme (an acronym for Congestive heart failure, Hypertension, Age 475 years, Diabetes mellitus, and previous Stroke or transient ischaemic attack). 12 Ischaemic stroke was defined as a neurological deficit of sudden onset that persisted for 424 h, corresponding to a vascular territory in the absence of primary haemorrhage, and was not explained by other causes (trauma, infection, vasculitis). 13 Patients with stroke that occurred during the initial hospitalization or as a complication of procedures were excluded from the analysis. This is because INR readings usually become fluctuant on admission due to medication adjustment or transient cessation of warfarin use.
Major bleeding was defined as intracranial bleeding, subarachoid haemorrhage, subdural haematoma, haemorrhagic transformation of a primary ischaemic stroke (as documented by computed tomogram scan, magnetic resonance imaging or autopsy), or any bleeding leading to at least 2 units of whole blood or erythrocytes, requiring surgical or angiographic intervention, resulting in permanent disability or involving a critical anatomic site. 14 Minor bleeding was defined as any bleeding clinically noticed not categorized as major bleeding, commonly presented as epistaxis, gastrointestinal bleeding, rectal bleeding, bruises and petechiae formation and haematuria. Any bleeding event, which resulted in admission to hospital, was defined as 'bleeding requiring hospitalization'.
Anticoagulation control
Anticoagulation control was determined by measurement of INR values. All INR testing were performed in the same laboratory using the same reagents. The INR values at each clinic visit and during hospital admission were retrieved from the medical record and data on the first 4 weeks of initiation of warfarin therapy were excluded from analysis.
Statistical analysis
Following a test of statistical normality, continuous variables were expressed as mean (±1 s.d.). Statistical comparisons were performed with Student's t-test or Fisher's exact test, as appropriate. KaplanMeier survival analysis with the log-rank test was used to calculate cumulative incidences of clinical events. Multivariate analyses were performed with an enter regression model in which each variable with a P-value p0.1 (based on the univariate analysis) was entered into the model. The analysis was performed with stratification made by separating patients into groups with and without hypertension. A subsidiary analysis was also performed using blood pressure as a continuous variable. Moving averages of event rates over time are given as a function of blood pressure, together with smoothing splines to illustrate unprejudiced relationships. A P-value o0.05 was considered statistically significant. All analyses of data were conducted using SPSS version 13.0.
To estimate the proportion of the time that a patient spent in each INR level, we assumed that the actual difference in INR between any two consecutive measurements was linear and the data were interpolated accordingly. 15 Time in target range for each patient was assessed by the percentage of interpolated INR values within the target range of 2.0-3.0. The anticoagulation control was considered moderate when percentage time of INR in target range was more than 60%, and good when the percentage was 475%. The incidence of ischaemic stroke, myocardial infarction and bleeding events were reported according to the INR value among patients who were taking warfarin. Incidence rates of ischaemic stroke and different bleeding complications (major and minor bleeding, bleeding requiring hospitalization and intracranial haemorrhage) for each specific level of INR were calculated by applying the following equation: 15 Number of events occurred at an INR level/number of total patientyears spent at the same INR level.
Results
Clinical characteristics of patients with or without hypertension are presented in Table 1 . Patients with non-valvular AF and hypertension had a higher CHADS score (Po0.001) and were more likely to be at moderate-high risk for ischaemic stroke (Po0.001), as compared with patients without hypertension ( Figure 1 ). There were no significant differences between the two groups with respect to age, sex, smoking status, the prevalence of diabetes, coronary heart disease, hyperlipidaemia, congestive heart failure and the use of antiplatelet agents, history of bleeding, anticoagulation control and patient follow-up years. Furthermore, the anticoagulation control was not significantly different between patients with or without hypertension.
Hypertension and ischaemic stroke
After a mean follow-up of 4.1±1.9 years, ischaemic stroke was observed in 28 (10.1%) patients with hypertension and in 13 (6.6%) patients without hypertension. The annual risks of ischaemic stroke were 2.5 and 1.6% per year, respectively. Figure 2a shows the Kaplan-Meier curves for the percentage of patients with stroke-free survival. There was no significant difference in the development of ischaemic stroke in patients with or without hypertension (hazard ratio (HR): 1.51, 95% confidence interval (CI): 0.79-2.78, P ¼ 0.22). Table 2 (HR: 4.6, 95% CI: 1.04-20.09, P ¼ 0.04) and high CHADS2 (HR: 1.5, 95% CI: 1.01-2.11, P ¼ 0.04) were independent risk factors for ischaemic stroke.
Hypertension and bleeding events A total of 70 bleeding episodes (33 major and 37 minor episodes) occurred during the follow-up period, of which 44 occurred in patients with hypertension (15.8%) and 26 in patients with no hypertension (13.1%). The annual bleeding risks were 3.9% per year in patients with hypertension and 3.2% per year in those without hypertension. Kaplan-Meier analysis demonstrated no significant differences in the occurrence of overall bleeding (HR: 1.25, 95% CI: 0.77-2.02, P ¼ 0.29; Figure 2b ), major bleeding (HR: 1.00, 95% CI: 0.50-1.99, P ¼ 0.99; Figure 2c ) and minor bleeding (HR: 1.44, 95% CI: 0.73-2.76, P ¼ 0.29; Figure 2d ) between patients with and without hypertension. There were 10 intracranial haemorrhage events during the follow-up period: 6 in patients with hypertension (2.2%) and 4 in patients without hypertension with annual incidence of 0.53 and 0.5 per year, respectively (HR: 1.11, 95% CI: 0.32-3.90, P ¼ 0.87; Figure 2e ). Table 3 Blood pressure control and ischaemic stroke risk Of 278 patients with hypertension, only 76 patients (27.3%) had a mean blood pressure achieving the target blood pressure (o130/80 mm Hg). There were no significant differences in the clinical characteristics and INR control between patients with or without achieving the target blood pressure (Table 4) . However, of the 28 ischaemic strokes during the study period, 3 (3.9%) occurred in patients achieving target blood pressure, and 25 (12.4%) occurred in patients not achieving target blood pressure, with annual ischaemic stroke risk of 0.9 and 3.1% per year, respectively. Figure 2f depicts the KaplanMeier curves for the cumulative ischaemic strokefree survival. Patients who did not achieve blood pressure control had a higher incidence of ischaemic stroke (HR: 5.0, 95% CI: 1.23-6.53, P ¼ 0.01).
In Cox regression analysis, only poor blood pressure control predicted the occurrence of stroke 
Discussion
Despite a higher CHADS2 score and risk of stroke in patients with hypertension, there was no significant difference in the incidence of ischaemic stroke on warfarin therapy as compared with normotensive AF patients. Furthermore, the use of anticoagulation therapy in Chinese patients with AF and hypertension did not increase the risk of minor or major bleeding, as compared with normotensive patients. These findings suggest that anticoagulation therapy is safe and effective in Chinese patients with hypertension as in normotensive patients. Furthermore, hypertensive patients with AF who achieved target blood pressure control of o130/80 mm Hg also had a significantly lower incidence of ischaemic stroke with anticoagulation therapy compared with those without achieving target blood pressure control.
The strong association between hypertension and stroke in patients with AF is probably mediated primarily by embolism originating in the left atrial appendage. Hypertension in patients with AF is associated with reduced left atrial appendage flow velocity, spontaneous echo contrast and thrombus formation. [16] [17] [18] On the other hand, hypertension per se can also increase the risk of non-cardioembolic strokes due to hyalinization of small vessels, fragility of vessels and lacunar infarct in patients with AF. 5, 6 A recent analysis from the Stroke Prevention using an ORal Thrombin Inhibitor in atrial Fibrillation Trial (SPORTIF) has shown that the risk of the systemic thromboembolism and stroke in patients with non-valvular AF increased with the level of systolic blood pressure. 19 It is possible that poorly controlled blood pressure might contribute an increased risk of ischaemic stroke and bleeding, especially intracranial bleeding in patients with non-valvular AF. 20, 21 Although no relationship between the risk of bleeding and the quartiles of systolic blood pressure was observed in the SPOR-TIF cohort, the impact of blood pressure control on the risk of ischaemic stroke and bleeding events were not investigated. 19 In this study, the incidences of ischaemic stroke in hypertensive and normotensive patients were comparable when the INR control was similar between the two groups. These findings suggest that thromboembolism is related to AF rather than hypertension per se is a more important determinant of ischaemic stroke in our patient cohort with AF. Nevertheless, a history of smoking, the presence of congestive heart failure and a higher CHADS2 score remained to be significant independent predictors for ischaemic stroke despite anticoagulation therapy. On the other hand, the use of antiplatelet therapy did not reduce the risk of ischaemic stroke but increase the risk of bleeding in AF patients treated with anticoagulation therapy. More importantly, among AF patients with hypertension, those who achieved target blood pressure control had a significantly lower risk of ischaemic stroke without any difference in bleeding. This is likely because anticoagulation therapy is less effective in preventing ischaemic stroke due to mechanisms other than thromboembolism, 19 and tightly controlled blood pressure might contribute to a reduced risk of ischaemic stroke related to hypertension per se. 5, 6 Therefore, other than the level of anticoagulation, good control of blood pressure are equally important for the prevention of ischaemic stroke in patients with AF and hypertension.
Limitations
The study has several limitations. First, there are inevitable limitations owing to the retrospective nature of this observational study. As the data collected are limited to the variables of clinical management, many desirable parameters were not included in the medical records of most subjects. Second, although we failed to show that hypertension was associated with ischaemic stroke, this would be related to the relatively small sample size. In addition, our cohort appeared to be younger than the usual AF population whose bleeding risk and ischaemic stroke are both higher than the present cohort; as a result, our observation lacks generalizability to this patient population.
